Adropin Hormone Links Circadian Rhythms to Metabolism and Mitochondrial Health

Adropin, a metabolic hormone discovered in 2008, has emerged as a key regulator linking circadian biology with metabolic health. This comprehensive study examined adropin expression patterns across diverse human tissues to understand its role in daily rhythms and metabolic processes.

Researchers analyzed gene expression data from multiple human tissue databases and examined plasma adropin levels in aging cohorts including the MAPT study. They used advanced bioinformatics approaches to map adropin expression patterns across tissues and correlate them with circadian, metabolic, and mitochondrial gene networks.

The study revealed that adropin expression follows distinct circadian patterns in metabolically active tissues like liver, muscle, and adipose tissue. Expression levels peaked during active periods and correlated strongly with genes involved in lipid metabolism, mitochondrial biogenesis, and energy production. Notably, adropin showed tissue-specific expression patterns that aligned with each tissue's metabolic function.

In human cohorts, plasma adropin levels varied with age and metabolic status. Lower adropin was associated with metabolic dysfunction markers including altered lipid profiles and reduced mitochondrial gene expression. The hormone's expression also correlated with circadian clock genes, suggesting it serves as a metabolic output of the body's internal timing system.

These findings position adropin as a potential biomarker for metabolic health and circadian function. The research suggests therapeutic strategies targeting adropin pathways could address age-related metabolic decline and circadian disruption, common features of aging and metabolic disease.